Jenny Holt | Chief Development Officer
Ray Therapeutics

Jenny Holt Chief Development Officer, Ray Therapeutics   Jenny Holt is Chief Development Officer at Ray Therapeutics. She has more than 25 years of life sciences expertise primarily in gene therapies, ophthalmology, and oncolytics. She joined Ray Therapeutics in 2022 as part of the executive team, and leads CMC, quality, & program management. Prior to joining RayTx,  Ms. Holt was VP and Head of program management at 4D Molecular Therapeutics, an AAV-based gene therapy company, where she managed five gene therapy products from discovery to early-stage clinical development. She was also a co-founder of Ignite Immunotherapy, an oncolytic immunotherapy company,  which was acquired by Pfizer in 2019. Ms. Holt has also been in various science and research roles at UCSF Gladstone Institutes, Onyx Pharmaceuticals, and Novartis Institute of Biomedical Research. She is a graduate of UC Santa Barbara.